References
- Swinnen LJ. Lymphoproliferative disorders following organ transplantation: clinical syndromes and treatment options. Epstein-Barr Virus Rep 1999;37:2852–2857.
- Baiocchi OC, Colleoni GW, Caballero OL, et al. Quantification of Epstein-Barr viral load and determination of a cut-off value to predict the risk of post-transplant lymphoproliferative disease in a renal transplant cohort. Haematologica 2004;89:366–368.
- Baiocchi OC, Colleoni GW, Caballero OL, et al. Epstein-Barr viral load, interleukin-6 and interleukin-10 levels in post-transplant lymphoproliferative disease: a nested case-control study in a renal transplant cohort. Leuk Lymphoma 2005;46:533–539.
- Gottenberg JE, Aucouturier F, Goetz J, et al. Serum-free light chain assessment in rheumatoid arthritis and primary Sjögren's syndrome. Ann Rheum Dis 2006;66:23–27.
- Terrier B, Sène D, Saadoun D, et al. Serum-free light chain assessment in hepatitis C virus-related lymphoproliferative disorders. Ann Rheum Dis 2008;68:89–93.
- Landgren O, Goedert JJ, Rabkin CS, et al. Circulating serum free light chains as predictive markers of AIDS-related lymphoma. J Clin Oncol 2010;28:773–779.
- Engels EA, Preiksaitis J, Zingone A, Landgren O. Circulating antibody free light chains and risk of posttransplant lymphoproliferative disorder. Am J Transplant 2012;12:1268–1274.
- Harris NL, Ferry JA, Swerdlow SH. Posttransplant lymphoproliferative disorders: summary of Society for Haematophathology workshop. Semin Diagn Pathol 1997;14:8–14.
- Cockcroft D, Gault MD. Prediction of creatinine clearance from serum creatinine. Nephron 1976:16:31–41.
- Tencer J, Thysell H, Andersson K, et al. Long-term stability of albumin, protein HC, immunoglobulin G, kappa- and lambda-chain immunoreactivity, orosomucoid and alpha 1-antitrypsin in urine stored at -20 degrees C. Scand J Urol Nephrol 1997;31:67–71.
- Katzmann JA, Clark RJ, Abraham RS, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clini Chem 2002;48:1437–1444.
- Hutchison CA, Harding S, Hewins P, et al. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol 2008;3:1684–1690.
- Ernster VL. Nested case-control studies. Prev Med 1994;23: 587–590.
- Campos ML, Carvalho NMB, Martín-Reyes G. The value of serum free light chain assay in patients with monoclonal gammopathies and renal failures. Nefrologia 2012;32:15–19.
- Bradwell AR. Serum free light chain analysis. 4th ed. Birmingham, UK: The Binding Site Ltd.; 2006.